GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » Repurchase of Stock

Incyte (BSP:I1NC34) Repurchase of Stock : R$0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Incyte Repurchase of Stock?

Incyte's Repurchase of Stock for the three months ended in Dec. 2023 was R$0 Mil.

Incyte's Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2023 was R$0 Mil.

Incyte Repurchase of Stock Historical Data

The historical data trend for Incyte's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Repurchase of Stock Chart

Incyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Incyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Incyte Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Incyte's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte (BSP:I1NC34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (BSP:I1NC34) » Definitions » Repurchase of Stock
Comparable Companies
SRPT UTHR RPRX TECH ROIV LEGN VKTX BMRN CERE ASND OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
INCY:USA 1INCY:Italy ICY:Germany
Address
1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Website
https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte (BSP:I1NC34) Headlines

No Headlines